Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1.

Abstract: The present invention relates to a toe correction device including an elastic body readily worn on the foot while preventing inadvertent removal thereof, a toe insertion opening formed in the front of the body for inserting each of the toes so as to expose the front part of the toes, and a thick resilient correction part arranged between adjacent toe insertion openings so as to correct the toes while the user is freely moving, and to massage the toes during walking, thus assisting the blood circulation.

Abstract: Disclosed is a non-slip footwear which comprises a main body formed of a flexible material and formed to surround the sole of a foot of a user and to open the top side of the foot; toe insertion holes formed of the flexible material, protruding from the front part of the main body so that toes of the foot are respectively inserted into the toe insertion holes; an non-slip outsole formed at the heel part of the main body and formed of foamed rubber having abrasion resistance, and having a thickness of 1 mm˜5 mm; and non-slip dots formed at the sole part of the main body and the non-slip outsole.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1.

Abstract: Disclosed is a non-slip footwear which comprises a main body formed of a flexible material and formed to surround the sole of a foot of a user and to open the top side of the foot; toe insertion holes formed of the flexible material, protruding from the front part of the main body so that toes of the foot are respectively inserted into the toe insertion holes; an non-slip outsole formed at the heel part of the main body and formed of foamed rubber having abrasion resistance, and having a thickness of 1 mm˜5 mm; and non-slip dots formed at the sole part of the main body and the non-slip outsole.

Abstract: The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Abstract: The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Abstract: The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Abstract: The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibitin mTOR.